Trade Vanda - VNDA CFD
Add to favourite- Summary
- Historical Data
Spread | 0.06 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 6.14 |
Open | 6.14 |
1-Year Change | -3.61% |
Day's Range | 6.09 - 6.2 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jul 25, 2024 | 6.13 | 0.13 | 2.17% | 6.00 | 6.30 | 5.98 |
Jul 24, 2024 | 6.14 | 0.01 | 0.16% | 6.13 | 6.30 | 6.13 |
Jul 23, 2024 | 6.26 | -0.02 | -0.32% | 6.28 | 6.31 | 6.15 |
Jul 22, 2024 | 6.29 | 0.21 | 3.45% | 6.08 | 6.33 | 6.03 |
Jul 19, 2024 | 6.07 | 0.09 | 1.51% | 5.98 | 6.12 | 5.91 |
Jul 18, 2024 | 6.04 | -0.04 | -0.66% | 6.08 | 6.29 | 5.87 |
Jul 17, 2024 | 6.19 | 0.08 | 1.31% | 6.11 | 6.22 | 6.09 |
Jul 16, 2024 | 6.19 | 0.19 | 3.17% | 6.00 | 6.22 | 6.00 |
Jul 15, 2024 | 5.99 | 0.25 | 4.36% | 5.74 | 6.05 | 5.74 |
Jul 12, 2024 | 5.90 | 0.10 | 1.72% | 5.80 | 5.93 | 5.74 |
Jul 11, 2024 | 5.78 | 0.43 | 8.04% | 5.35 | 5.87 | 5.35 |
Jul 10, 2024 | 5.19 | -0.12 | -2.26% | 5.31 | 5.34 | 5.11 |
Jul 9, 2024 | 5.29 | 0.10 | 1.93% | 5.19 | 5.32 | 5.17 |
Jul 8, 2024 | 5.24 | -0.01 | -0.19% | 5.25 | 5.36 | 5.21 |
Jul 5, 2024 | 5.20 | -0.06 | -1.14% | 5.26 | 5.29 | 5.14 |
Jul 3, 2024 | 5.22 | -0.03 | -0.57% | 5.25 | 5.40 | 5.22 |
Jul 2, 2024 | 5.23 | -0.32 | -5.77% | 5.55 | 5.56 | 5.19 |
Jul 1, 2024 | 5.56 | -0.05 | -0.89% | 5.61 | 5.76 | 5.55 |
Jun 28, 2024 | 5.62 | -0.19 | -3.27% | 5.81 | 5.81 | 5.42 |
Jun 27, 2024 | 5.80 | 0.08 | 1.40% | 5.72 | 5.90 | 5.72 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Vanda Company profile
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its commercial portfolio consists of two products, HETLIOZ (tasimelteon) for the treatment of jet lag disorder, pediatric non-24, delayed sleep phase disorder (DSPD) and autism spectrum disorder (ASD), and Fanapt (iloperidone) for the treatment of bipolar disorder and Parkinson's disease psychosis (PDP) and a long acting injectable (LAI) formulation for the treatment of schizophrenia. Its other product pipeline includes Tradipitant (VLY-686), VTR-297, VSJ-110 and BPO-27. VLY-686, is for the treatment of gastroparesis, motion sickness, atopic dermatitis and COVID-19 pneumonia. VTR-297, is for the treatment of hematologic malignancies. VSJ-110, is for the treatment of dry eye and ocular inflammation. BPO-27, is for the treatment of secretory diarrhea disorders, including cholera. Its other product includes VQW-765.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Vanda Pharmaceuticals Inc. revenues increased 8% to $268.7M. Net income increased 42% to $33.2M. Revenues reflect Hetlioz segment increase of 8% to $173.5M, Fanapt segment increase of 9% to $95.1M. Net income benefited from Selling, General and administrative - decrease of 10% to $105.9M (expense), Advertising Expenses decrease of 47% to $6.7M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 150M auth., 28,103,441 issd. Insiders own 1.56%. 4/18/06 IPO: 5.8M shs. @ $10 per shareby JP Morgan Securities, Inc.
Industry: | Bio Therapeutic Drugs |
Suite 300E
2200 Pennsylvania Ave Nw
WASHINGTON
WASHINGTON DC 20037
US
News
![](https://img.capital.com/imgs/articles/192x130x1/Risk-Management-in-Trading.png)
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024![](https://img.capital.com/imgs/articles/192x130x1/ECB_0.png)
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024![](https://img.capital.com/imgs/articles/192x130x1/risk_2_1_optimized_450_1.png)
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024![](https://img.capital.com/imgs/articles/192x130x1/Stock-1-_1.png)
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024![](https://img.capital.com/imgs/articles/192x130x1/ETF-1-_0.png)
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024![Lloyds share price forecast: An attractive dividend stock? Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/192x130x1/shutterstock_536730610_0.jpg)
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024![](https://img.capital.com/imgs/articles/192x130x1/RBNZ.png)
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com